Rennova Health, Inc. · OTC:RNVA
Rennova Health — Investor Presentation (July 2017)
21 slides from Rennova Health's investor presentation, July 2017
Slide 1: Diagnostics and Supportive Software Solutions to Healthcare Providers
July 2017 Nasdaq: Common stock RNVA Warrants (July 2021) RNVAZ Diagnostics and Supportive Software Solutions to Healthcare Providers
Slide 2: Forward Looking Statements and Non-GAAP Information
Forward Looking Statements and Non-GAAP Information This presentation includes forward-looking statements about Rennova Health’s anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, obj
Slide 3: Healthcare is Being Transformed
Healthcare is Being Transformed We are Rennova Health 3
Slide 4: Key Investment Highlights
Key Investment Highlights • Five-year history of operations in clinical laboratory space • Toxicology • Clinical • Genetic testing including pharmacogenomics and oncology • Three years in software development for the medical sector • Proprietary lab ordering and reporting • Lab information systems •
Slide 5: Rennova Offers a Single Source Solution for Medical Providers
Rennova Offers a Single Source Solution for Medical Providers • The diagnostics sector has changed dramatically in the last few years • Paper records and faxes meant different vendors to a medical provider could function side by side without communication • Electronic platforms and integration have
Slide 6: Rennova Offers a Single Source Solution for Medical Providers
Rennova Offers a Single Source Solution for Medical Providers Clinical Lab Services 5 Clinical Laboratories Single Source Solution Revenue Software Cycle Solutions Management Proprietary Lab ordering and reporting Laboratory Information System (LIS) Integrated Medical Billing Company Creates opportu
Slide 7: Recent Developments
Recent Developments Clinical Laboratory Operations Segment • Transitioned from focus on toxicology to expanded menu of clinical diagnostics • Acquired CollabRx and Genomas for their technology in the oncology interpretation market and the pharmacogenomics testing sector • Hospital acquisition comple
Slide 8: Recent Developments
Recent Developments Supportive Software Solutions Segment • Our integrated software solution creates a much more sustainable relationship with our customers • EHR product launched in substance abuse sector last quarter 2015 Revenue Cycle Management • We launched a specialized division to provide med
Slide 9: Our Target Markets
Our Target Markets Drug and Alcohol Rehabilitation • Total Market Size – estimated at $35 Billion* • Large and growing number of facilities in a fragmented market • Between 14,500 to 16,700 outpatient clinics* Market growth from high demand: • Over 23 million Americans are addicted to alcohol and ot
Slide 10: Rennova Health Licensing Map
Rennova Health Licensing Map 10
Slide 11: Our Payers
Our Payers • Initiated Medicaid Licensing & Third Party Payer Initiative in December 2015 o Applied for Medicaid Licenses in 34 States o We possess Medicaid Licenses in 28 States • Current Third Party Insurance Payer Contracts o Blue Shield of California o Fortified Provider Network o Coventry (Nati
Slide 12: History in Numbers
History in Numbers ($000’s) 70,000 59,429 60,000 50,000 41,889 37,877 40,000 30,000 19,749 20,000 14,775 10,000 6,245 1,386 0 (10,000) (20,000) (30,000) (25,216) 2013 2014 2015 2016 Adjusted Revenues Adjusted EBITDA 12
Slide 13: Select Income Statement Items
Select Income Statement Items (in thousands) 2013 2014 2015 2016 GAAP Net Revenue $ 41,889 $ 57,928 $ 18,393 $ 5,245 Reserve for Aged Accounts Receivable - 1,501 19,494 1,000 Adjusted Revenues $ 41,889 $ 59,429 $ 37,887 $ 6,245 GAAP Pretax Income (Loss) $ 13,829 $ 15,382 $ (44,991) $ (32,400) Deprec
Slide 14: Strategy
Strategy 14
Slide 15: The Long Term Strategy
The Long Term Strategy Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders How? Build from a toxicology-focused company to: 1. A significant and diverse diagnostics business including the provision of “needed services” from ownership o
Slide 16: 2017 Goals
2017 Goals • Strengthen Core Diagnostic Business o Plan to open our 1st hospital o Continue to capitalize on the disruption in toxicology sector o Increase Clinical testing o Grow Pharmacogenomics testing with Genomas o Launch DTC (Direct to Consumer) testing o Consider opportunities for acquisition
Slide 17: Our goal in numbers
Our goal in numbers • We believe that we can achieve the following revenues for 2018 o $600K per month for toxicology and clinical diagnostics o $400K per month for software and RCM related revenue o $1M per month from our hospital in TN Subject to acquisition o $800K per month from Dr’s practices o
Slide 18: Rennova Management
Rennova Management Seamus Lagan • 20 years experience in the restructuring, development and CEO management of startup and small companies Victoria Nemerson, Esq. • 25 years experience as a compliance and healthcare General Counsel attorney Scott Jenkins • Prior CEO Positions at Alchemist Ventures, C
Slide 19: Board of Directors (July 2017)
Board of Directors (July 2017) • 20 years experience in the restructuring, development and Seamus Lagan management of startup and small companies CEO • Founder, investor and shareholder • Chairman and CEO of Integrated Financial Settlements, Inc., a Christopher Diamantis structured settlement consul
Slide 20: Capitalization July 11th 2017
Capitalization July 11th 2017 Capitalization Table 11-Jul-17 Common Shares Issuable upon Exercise/ Conversion Common Stock 14,473,360 14,473,360 Series G Preferred Stock 215 15,926 Series H Preferred Stock 60 153,847 Convertible Debentures 12,943,674.00 33,188,907 warrants with an exercise price of
Slide 21: Key Investment Highlights
Key Investment Highlights • Five-year history of operations in clinical laboratory space • Toxicology • Clinical • Genetic testing including pharmacogenomics and oncology • Three years in software development for the medical sector • Proprietary lab ordering and reporting • Lab information systems •